This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
CVS Health (CVS) Down 14.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS), backed by the announcement of entering into a colossal $10.6-billion acquisition agreement to purchase Oak Street Health.
Is Trending Stock CVS Health Corporation (CVS) a Buy Now?
by Zacks Equity Research
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Zacks Analyst Blog Highlights Mastercard, Raytheon Technologies, BP, CVS Health and Uber Technologies
by Zacks Equity Research
Mastercard, Raytheon Technologies, BP, CVS Health and Uber Technologies are included in this Analyst Blog.
Top Research Reports for Mastercard, Raytheon Technologies & BP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Raytheon Technologies Corporation (RTX) and BP p.l.c. (BP).
CVS Health's (CVS) New Acquisitions Aid, Cost Woes Linger
by Zacks Equity Research
CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.
Here's Why CVS Health (CVS) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Is It Worth Investing in CVS Health (CVS) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), CVS Health (CVS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
CVS Health (CVS) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
CVS Health's (CVS) Retail/LTC segment revenues rise on increased prescription and front store volume, pharmacy drug mix and brand inflation.
CVS Health (CVS) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for CVS Health (CVS) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CVS Health (CVS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of 3.65% and 11.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Time to Buy CVS Stock Before Crucial Q4 Earnings?
by Shaun Pruitt
Trading near its 52-week lows and 23% from its highs, investors will be paying close attention to CVS Health's (CVS) fourth-quarter earnings on February 8.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $86.18 in the latest trading session, marking a -1.5% move from the prior day.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Health (CVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Apple, Meta Platforms, Mastercard, CVS Health and Ameriprise Financial
by Zacks Equity Research
Apple, Meta Platforms, Mastercard, CVS Health and Ameriprise Financial are included in this Analyst Blog.
Q4 Earnings Season Scorecard and Analyst Reports for Apple, Meta & Mastercard
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Meta Platforms, Inc. (META) and Mastercard Incorporated (MA).
Here's Why CVS Health (CVS) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $87.78 in the latest trading session, marking a +0.14% move from the prior day.
CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q4.
CVS Health (CVS) to Expand Health Care Access With New Pact
by Zacks Equity Research
CVS Health's (CVS) recent collaboration establishes new Accountable Care that focuses on health equity, coordinated care and enhanced access.
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon are part of the Zacks Industry Outlook article.
Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
3 Retail Pharmacy and Drugstore Stocks to Watch Amid Industry Headwinds
by Urmimala Biswas
The Zacks Retail Pharmacy and Drugstore industry players like CVS, WBA and RAD are likely to gain despite reimbursement challenges hurting the overall industry health.